

Financial news for MDVN dated on 2016-12-21: Breaking Down The Crowded Novel Ovarian Cancer Treatment Space

Financial news for MDVN dated on 2016-10-21: Medivation XTANDI Drug Has PDUFA Date Of Oct. 22 For Label Update With Earlier-Stage Use Data

Financial news for MDVN dated on 2016-09-23: Pfizer Reports Expiration of HSR Waiting Period for Proposed Deal of Medivation

Financial news for MDVN dated on 2016-09-21: More Pharma Deals In The Pipeline?

Financial news for MDVN dated on 2016-09-16: TESARO Shares Trading Up ~2% in Otherwise Down Tape on No News; Some Traders Getting Anxious Following News of Gilead \$5B Senior Notes Offering Announced Thurs. Evening

Financial news for MDVN dated on 2016-09-13: 'Delivering Alpha' Conference Has Been Known To Move Stocks

Financial news for MDVN dated on 2016-08-29: In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated

Financial news for MDVN dated on 2016-08-27: Here Are All The Big Biotech Mergers In 2016

Financial news for MDVN dated on 2016-08-24: Pfizer's \$1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?

Financial news for MDVN dated on 2016-08-24: Risk Arbitrage Trading Strategies

Financial news for MDVN dated on 2016-08-24: Write A Prescription For More Pharma M&A With This ETF

Financial news for MDVN dated on 2016-08-23: Pfizer Has Had A Busy M&A Year...Or Has It?

Financial news for MDVN dated on 2016-08-22: Benzinga's M&A Chatter for Monday August 22, 2016

Financial news for MDVN dated on 2016-08-22: Monday's Market Wrap: Stocks Closed Mixed In Quiet Trade

Financial news for MDVN dated on 2016-08-22: Mid-Afternoon Market Update: CIFC Rises Following Acquisition News; Marathon Oil Shares Slide

Financial news for MDVN dated on 2016-08-22: 10 Biggest Mid-Day Gainers For Monday

Financial news for MDVN dated on 2016-08-22: Wedbush Downgrades Medivation to Neutral, Raises to \$81.50

Financial news for MDVN dated on 2016-08-22: Mid-Day Market Update: Crude Oil Down 2.8%; Intersil Shares Spike Higher

Financial news for MDVN dated on 2016-08-22: Brean Capital Downgrades Medivation to Hold

Financial news for MDVN dated on 2016-08-22: Barclays Downgrades Medivation to Equal-weight, Raises PT to \$81.00

Financial news for MDVN dated on 2016-08-22: Benzinga's Volume Movers

Financial news for MDVN dated on 2016-08-22: Mid-Morning Market Update: Markets Mostly Lower; Pfizer To Buy Medivation For \$14 Billion

Financial news for MDVN dated on 2016-08-22: The Market In 5 Minutes: Indexes Remain In Tight Range As Rio Olympics Come To An End

Financial news for MDVN dated on 2016-08-22: 5-Month Timeline: A Look Back At Medivation's Takeover Story

Financial news for MDVN dated on 2016-08-22: Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation

Financial news for MDVN dated on 2016-08-22: 8 Stocks Moving In Monday's Pre-Market Session

Financial news for MDVN dated on 2016-08-22: Pfizer Has Emerged The Victor In The Buyout Battle For Medivation

Financial news for MDVN dated on 2016-08-22: A Peek Into The Markets: U.S. Stock

Futures Down; Crude Oil Drops 2.7%

Financial news for MDVN dated on 2016-08-22: Pfizer Buys Medivation For \$14 Billion, Accelerating Its Pathway To Be A Leader In Oncology

Financial news for MDVN dated on 2016-08-22: Pfizer To Acquire Medivation For \$81.50/Share Cash

Financial news for MDVN dated on 2016-08-22: Must Watch Stocks for August 22, 2016

Financial news for MDVN dated on 2016-08-22: Medivation +20% Premarket @\$81; FT Reported on Sunday Pfizer to Offer ~\$80/Share

Financial news for MDVN dated on 2016-08-21: Pfizer to Pay ~\$80/Share For Medivation -Reuters

Financial news for MDVN dated on 2016-08-17: UPDATE: Reuters Says Merck, Sanofi, Pfizer, Gilead, Celgene Have Each Submitted Expressions of Interest for Medivation

Financial news for MDVN dated on 2016-08-17: Medivation Shares Now Up 1.4% as Reuters Reports Several Cos. Have Expressed Interest in Co.

Financial news for MDVN dated on 2016-08-16: Watch These 10 Huge Call Purchases In Tuesday Trade

Financial news for MDVN dated on 2016-08-15: Option Alert: MDVN Sep16 65.0 Calls: 2450 @ Above Ask! \$3.00: 2790 traded vs 23k OI: \$65.21 Ref

Financial news for MDVN dated on 2016-08-15: Option Alert: MDVN Sep16 65.0 Calls: 2500 @ Above Ask! \$3.00: 2790 traded vs 23k OI: \$65.27 Ref

Financial news for MDVN dated on 2016-08-11: Medivation Pops to High of \$65.57

Financial news for MDVN dated on 2016-08-11: UPDATE: Pfizer, Sanofi, German Bidder Said to be Competing for Medivation

Financial news for MDVN dated on 2016-08-11: Hearing Medivation Sales Process in Final Stages

Financial news for MDVN dated on 2016-08-10: The Market In 5 Minutes: Stocks Still In Tight Range, Disney And Michael Kors Fall On Earnings

Financial news for MDVN dated on 2016-08-10: JMP Securities Downgrades Medivation to Market Perform

Financial news for MDVN dated on 2016-08-09: Medivation Sees FY16 EPS \$1.30-\$1.40 vs. Est. \$1.40; Sees \$1.425-\$1.525B In U.S. Net Sales Of XTANDI

Financial news for MDVN dated on 2016-08-09: Medivation Reports Q2 EPS \$0.29 vs. Est. \$0.27, Rev. \$206.2M vs. Est. \$212.7M

Financial news for MDVN dated on 2016-08-09: Option Alert: MDVN Sep16 \$50 Puts 2,575 @ BID @ \$0.65

Financial news for MDVN dated on 2016-08-04: Benzinga's M&A Chatter for Thursday August 4, 2016

Financial news for MDVN dated on 2016-08-02: Watch These 10 Huge Call Purchases In Tuesday Trade

Financial news for MDVN dated on 2016-08-01: Option Alert: MDVN Sep16 70.0 Calls: 5000 @ ASK \$1.00: 5153 traded vs 16k OI: Earnings 8/9 After Close \$64.09 Ref

Financial news for MDVN dated on 2016-07-29: CNBC Now @CNBCnow Tweet: NEW: Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - sources

Financial news for MDVN dated on 2016-07-28: Short-Sellers Shy Away From These 2 Biotechs This Settlement Period

Financial news for MDVN dated on 2016-07-22: The Market In 5 Minutes: The Dow's Win Streak Comes To An End

Financial news for MDVN dated on 2016-07-21: Benzinga's M&A Chatter for Thursday July 21, 2016:

Financial news for MDVN dated on 2016-07-21: Technical Alert: Medivation Shares Flirted with \$62.50 Level Following Rumor Pfizer Could Pose Rival Bid; Watch for Support Level Around \$62.14 Level on Downside, Watch for Resistance at Jul. 7 High of

\$62.98

Financial news for MDVN dated on 2016-07-21: Medivation Spikes to High of \$63.23 on Pfizer Takeover Rumor

Financial news for MDVN dated on 2016-07-21: Traders Attributing Spike Higher in Medivation to Unconfirmed Chatter of Rival Bid from Pfizer

Financial news for MDVN dated on 2016-07-18: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for MDVN dated on 2016-07-15: Option Alert: MDVN Sep16 65.0 Calls: 4000 @ Above Ask! \$2.38: 15k traded vs 5310 OI: Earnings 7/26 After Close \$61.79 Ref

Financial news for MDVN dated on 2016-07-15: Option Alert: Unusual Call Spread Activity in Medivation; Sep \$65/\$75

Financial news for MDVN dated on 2016-07-12: 6 Largest Price Target Changes For Tuesday

Financial news for MDVN dated on 2016-07-12: Wedbush Previews Medivation's Q2 Earnings, Sees Takeout In Mid- To High-\$60 Range

Financial news for MDVN dated on 2016-07-07: Medivation Bidders Will Have To Price In Talazoparib; BMO Sees \$68-\$76 Takeout Price

Financial news for MDVN dated on 2016-07-07: Adam Feuerstein @adamfeuerstein Tweet: @TerryMSmith @Sport234a \$BMRN does get royalty on tala sales, so if that \$30B mkt opportunity promised by \$MDVN comes true... \$\$\$

Financial news for MDVN dated on 2016-07-07: Credit Suisse Says Medivation Market Value Is Approaching Its Target

Financial news for MDVN dated on 2016-07-06: From Medivation Call: Hung Says Won't be Taking Questions Regarding Takeover Offers

Financial news for MDVN dated on 2016-07-06: From Medivation Call: CEO David T. Hung, Says Talazoparib is a \$1B Opportunity

Financial news for MDVN dated on 2016-07-06: Medivation Call on Talazoparib Begins

Financial news for MDVN dated on 2016-07-06: Medivation Releases Presentation on Talazoparib; Conference Call to Begin at 4:30 PM ET

Financial news for MDVN dated on 2016-07-06: Option Alert: MDVN 4,950 Jul \$65 Call @Bid @\$0.30

Financial news for MDVN dated on 2016-07-06: The Market In 5 Minutes: Gold Hits Highest Level Since 2014

Financial news for MDVN dated on 2016-07-06: Medivation to Hold Talazoparib Investor Call at 4:30 PM ET Wednesday

Financial news for MDVN dated on 2016-07-06: Stocks To Watch For July 6, 2016

Financial news for MDVN dated on 2016-07-05: Benzinga's M&A Chatter for Tuesday July 5, 2016

Financial news for MDVN dated on 2016-07-05: Hearing Pfizer, Celgene Signed Medivation Confidentiality Deals

Financial news for MDVN dated on 2016-07-05: UPDATE: MEDIVATION Acquisition Proposal Was For \$58 per share in Cash

Financial news for MDVN dated on 2016-07-05: UPDATE: Medivation Expresses Interest In Exploring a Potential Transaction And Demonstrated Interest To Board's Satisfaction

Financial news for MDVN dated on 2016-07-05: Medivation Enters into Confidentiality Agreements, Including with Sanofi; Sanofi To Terminate Its Consent Solicitation

Financial news for MDVN dated on 2016-07-05: Medivations in Talks With Sanofi Following Sweetened Offer

Financial news for MDVN dated on 2016-06-28: Sanofi Sounding Out Medivation Shareholder; Preparing to Raise Offer -CNBC

Financial news for MDVN dated on 2016-06-27: Betaville's Ben Harrington Says Sanofi Could bid for Biomarin if Medivation Bid Fails

Financial news for MDVN dated on 2016-06-24: Glass Lewis Urges Medivation Shareholders To Vote For Current Board

Financial news for MDVN dated on 2016-06-23: Medivation Sends Letter to Stockholders to Set Record Straight on Sanofi's Misleading Claims

Financial news for MDVN dated on 2016-06-23: The Market In 5 Minutes: It's Brexit Time

Financial news for MDVN dated on 2016-06-22: Benzinga's M&A Chatter for Wednesday June 22, 2016

Financial news for MDVN dated on 2016-06-22: Hearing Sanofi Will Consider Adding Contingent Value Right Payments to Offer for Medivation

Financial news for MDVN dated on 2016-06-22: Medivation Shares Up ~\$0.30-\$0.40 Over Last Few Mins

Financial news for MDVN dated on 2016-06-20: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for MDVN dated on 2016-06-17: Wedbush Analyst Says Sanofi Could Not Feasibly Drop Its Bid For Medivation To Shift Sight To Biomarin

Financial news for MDVN dated on 2016-06-17: Option Alert: MDVN Sep16 55.0 Puts: 4000 @ Above Ask! \$3.40: 5303 traded vs 716 OI: Earnings 8/4 \$59.44 Ref

Financial news for MDVN dated on 2016-06-17: Option Alert: MDVN Jul16 55.0 Puts: 1000 @ Above Ask! \$1.41: 1010 traded vs 3514 OI: Earnings 8/4 \$59.36 Ref

Financial news for MDVN dated on 2016-06-16: Medivation Prescription Growth And Potential Price Increases Could Drive Upside This Year

Financial news for MDVN dated on 2016-06-16: Medivation Reports Pidilizumab Shows Potential Clinical Benefit, Safety in Children with DIPG

Financial news for MDVN dated on 2016-06-14: Sanofi Announces Expiration of Hart-Scott-Rodino Waiting Period Regarding Proposed Acquisition of Medivation

Financial news for MDVN dated on 2016-06-08: The Market In 5 Minutes: Crude Oil Hits Highest Level In Nearly A Year

Financial news for MDVN dated on 2016-06-08: Sanofi Says if Medivation Were to Engage and Provide Additional Information, It Would be in a Position to Increase Offer

Financial news for MDVN dated on 2016-06-08: Sanofi Releases Presentation of Proposed Medivation Acquisition

Financial news for MDVN dated on 2016-06-06: Medivation Shares Volatile, Hearing Co Shared Or Displayed Suboptimal Tox For PARP Inhibitor

Financial news for MDVN dated on 2016-06-06: UPDATE: Medivation Shares Fall ~0.5% Over Last Few Mins as Near-Term Support Level at \$60 Fails to Hold

Financial news for MDVN dated on 2016-06-06: Medivation Sells Off to Low of \$59.29 on Vol

Financial news for MDVN dated on 2016-06-02: Medivation, Astellas Announce Initiation of Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer

Financial news for MDVN dated on 2016-06-01: Medivation Sets Record Date of June 1, 2016 for Sanofi's Proposed Consent Solicitation

Financial news for MDVN dated on 2016-06-01: Medivation Sets June 1, 2016 as Record Date for Sanofi Consent Solicitation

Financial news for MDVN dated on 2016-06-01: UPDATE: Sanofi Says Latest Medivation Board Can Set Record Date is Jun. 22, 2016

Financial news for MDVN dated on 2016-06-01: Sanofi Issues Release Disclosing It Has Submitted Written Notice to Secretary of Medivation Requesting Fix of Record Date

Financial news for MDVN dated on 2016-06-01: CNBC Now Tweets: Sanofi expected to request record date from Medivation today - sources (via @davidfaber)

Financial news for MDVN dated on 2016-05-27: UPDATE: Medivation Says Sanofi Hand-Picked Nominees Have Minimal Biotech Experience, Medivation Says Board Of Directors Has Rewarded Stockholders With Extraordinary Returns

Financial news for MDVN dated on 2016-05-27: UPDATE: Medivation Urges Holders to Mail GREEN Consent Solicitation Card

Financial news for MDVN dated on 2016-05-27: Medivation Reports Filing of Prelim. Proxy Statement to Contested Solicitation

Financial news for MDVN dated on 2016-05-26: Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?

Financial news for MDVN dated on 2016-05-25: Benzinga's M&A Chatter for Wednesday May 25, 2016

Financial news for MDVN dated on 2016-05-25: Medivation Advises Its Shareholders To Spurn Sanofi's Move To Replace Entire Board

Financial news for MDVN dated on 2016-05-25: Option Alert: MDVN Jun16 60.0 Calls Sweep: 500 @ ASK \$4.35: 610 traded vs 23k OI: \$61.94 Ref

Financial news for MDVN dated on 2016-05-25: Celgene, Gilead Said to Bid for Medivation -Bloomberg

Financial news for MDVN dated on 2016-05-25: The Market In 5 Minutes: Bold Moves

Financial news for MDVN dated on 2016-05-25: Sanofi Names Candidates, Committed To Replacing Medivation's Entire Board

Financial news for MDVN dated on 2016-05-25: Medivation Urges Stockholders to Reject Sanofi's Attempt to Replace Medivation Board of Directors

Financial news for MDVN dated on 2016-05-25: Sanofi Reports Filing of Consent Solicitation to Remove, Replace Medivation Board

Financial news for MDVN dated on 2016-05-25: UPDATE: Sanofi Nominees for Medivation Board Include Michael Campbell, Barbara Deptula, Wendy Lane, Ronald Rolfe, Steven Shulman, Charles Slacik, James Tyree, David Wilson

Financial news for MDVN dated on 2016-05-25: Sanofi Says Soliciting Consents from Medivation Shareholders to Take Actions Including 8 Directors Elected By Board Before Proposal Effectiveness Is Removed

Financial news for MDVN dated on 2016-05-25: Sanofi to Increase Efforts in China -Reuters

Financial news for MDVN dated on 2016-05-25: Sanofi to Name Nominees to Replace Medivation Board as Soon as Wednesday

Financial news for MDVN dated on 2016-05-24: Expect Volatility in Medivation Shares For Remainder of Today's Session as Benzinga Newsdesk Has Been Contacted By Source Familiar with Matter Suggesting Co. May Announce It Received an Offer from Another Bidder

Financial news for MDVN dated on 2016-05-17: A Look At All Of Pfizer's Acquisitions Over The Past 2 Years

Financial news for MDVN dated on 2016-05-17: Medivation Provides Update to Employees

Financial news for MDVN dated on 2016-05-13: Sanofi Wants To Replace The Entire Medivation Board, To Have Nominee Slate Ready By End Of Next Week-CNBC David Faber's Sources

Financial news for MDVN dated on 2016-05-12: Option Alert: MDVN Jun16 60.0 Calls Sweep: 1000 @ ASK \$4.50: 1331 traded vs 19k OI: \$60.67 Ref

Financial news for MDVN dated on 2016-05-12: Sanofi Files for Premerger Notification Under HSR for Medivation Acquisition

Financial news for MDVN dated on 2016-05-11: Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

Financial news for MDVN dated on 2016-05-10: The Market In 5 Minutes: Better Late Than Never

Financial news for MDVN dated on 2016-05-10: Report: Medivation Committed To Selling Itself

Financial news for MDVN dated on 2016-05-09: Benzinga's M&A Chatter for Monday May 9, 2016

Financial news for MDVN dated on 2016-05-09: Medivation Spikes to High of \$62.48 on Reuters Report of NDA's With Pfizer, Amgen

Financial news for MDVN dated on 2016-05-09: Medivation Decides to Explore Sale, Signs NDA With Pfizer, Amgen -Reuters

Financial news for MDVN dated on 2016-05-06: Barclays Lays Out Its Sum-Of-The-Parts Analysis On Medivation, Boosts Target Price By \$22

Financial news for MDVN dated on 2016-05-06: Option Alert: MDVN May16 65.0 Calls Sweep: 848 @ ASK \$0.65: 1649 traded vs 405 OI: \$59.98 Ref

Financial news for MDVN dated on 2016-05-06: Medivation's Take-Out Price Raised To \$68-\$78 At Citi

Financial news for MDVN dated on 2016-05-06: If Medivation Is Sold, Brean Thinkers It'll Be For Far More Than Sanofi's Bid

Financial news for MDVN dated on 2016-05-06: The Market In 5 Minutes: The Most Exciting Two Minutes In Sports

Financial news for MDVN dated on 2016-05-06: Benzinga's Top Upgrades

Financial news for MDVN dated on 2016-05-06: What's M&A Like In The Biotech Sector Right Now?

Financial news for MDVN dated on 2016-05-06: Medivation Execs Making A Strong Case For Independent Growth Vs. Sale, Credit Suisse Says

Financial news for MDVN dated on 2016-05-06: Citigroup Upgrades Medivation to Buy, Raises PT to \$73.00

Financial news for MDVN dated on 2016-05-05: Benzinga's M&A Chatter for Thursday May 5, 2016

Financial news for MDVN dated on 2016-05-05: Medivation Sees FY16 Adj. EPS \$1.30-\$1.40 vs \$1.32 Est., Sales \$900M-\$970M vs \$937M Est.

Financial news for MDVN dated on 2016-05-05: Medivation Reports Q1 Adj. EPS \$0.11 vs \$0.23 Est., Adj. Sales \$182.5M vs \$196.6M Est.

Financial news for MDVN dated on 2016-05-05: Option Alert: MDVN May16 60.0 Calls Sweep: 628 @ ASK \$2.00: 1005 traded vs 5054 OI: Earnings today After Close \$59.76 Ref

Financial news for MDVN dated on 2016-05-05: Medivation Reiterates Rejection Of Sanofi's Inadequate Proposal To Buy It

Financial news for MDVN dated on 2016-05-05: Medivation Reiterating Rejection of Sanofi Offer, Says Board Believes It Can Deliver Shareholder Value Above And Beyond What Sanofi Is Offering

Financial news for MDVN dated on 2016-05-05: Amgen Said to be Among Potential Bidders for Medivation -Bloomberg

Financial news for MDVN dated on 2016-05-05: Medivation Spikes to High of \$60.40 on Vol

Financial news for MDVN dated on 2016-05-05: UPDATE: Sanofi CEO to Medivation Board: 'If you are not prepared to engage with us, we have no choice but to go directly to your shareholders.'

Financial news for MDVN dated on 2016-05-05: UPDATE: Sanofi's Letter to Medivation's Board of Directors

Financial news for MDVN dated on 2016-05-05: UPDATE: Sanofi Says Could be in Position to Revise Offer for Medivation

Financial news for MDVN dated on 2016-05-05: UPDATE: Sanofi Says Acquisition of Medivation is a Priority

Financial news for MDVN dated on 2016-05-05: Sanofi Sends Letter to Medivation's Board of Directors

Financial news for MDVN dated on 2016-05-04: Mizuho Downgrades Relaysa, Says Near-Term Takeout 'Unlikely'

Financial news for MDVN dated on 2016-05-04: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MDVN dated on 2016-05-03: Benzinga's M&A Chatter for Tuesday May 3, 2016

Financial news for MDVN dated on 2016-05-03: Pfizer has Approached Medivation Regarding Potential Acquisition -Reuters

Financial news for MDVN dated on 2016-05-03: Hearing Pfizer Has Approached Medivation

Financial news for MDVN dated on 2016-05-02: Stifel Lays Out 3 Scenarios For Medivation Takeover

Financial news for MDVN dated on 2016-05-02: Jefferies Lifts Target On Medivation To \$52 From \$39 As 'Xtandi Looking Better'

Financial news for MDVN dated on 2016-05-01: Benzinga's Weekend M&A Chatter

Financial news for MDVN dated on 2016-04-29: \$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There

Financial news for MDVN dated on 2016-04-29: Here's What Medivation Said In Its Rejection Letter To Sanofi

Financial news for MDVN dated on 2016-04-29: Pfizer Spokesperson Declines Comment Following Bloomberg Report Co. is One of Several Cos. Working with Advisors for Possible Medivation Bid

Financial news for MDVN dated on 2016-04-29: UPDATE: Novartis Also Said to be Considering Options with Advisors for Potential Medivation Bid

Financial news for MDVN dated on 2016-04-29: Hearing Medivation Seeking Bids of At Least \$65/Share, AstraZeneca, Pfizer Mentioned as Weigh Bids

Financial news for MDVN dated on 2016-04-29: Pfizer Shares Also Spiked Slightly Higher with Medivation, Novartis Moves

Financial news for MDVN dated on 2016-04-29: Novartis Shares Tick Slightly Higher as Medivation Spikes Sharply Higher

Financial news for MDVN dated on 2016-04-29: Medivation Shares Spiking Higher

Financial news for MDVN dated on 2016-04-29: Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal For \$52.50/Share Cash, Undervalues Medivation And Not In Best Interest Of Shareholders

Financial news for MDVN dated on 2016-04-28: Benzinga's M&A Chatter for Thursday April 28, 2016

Financial news for MDVN dated on 2016-04-28: Why Medivation Will Likely Reject Sanofi's \$52.50/Share Buyout Offer

Financial news for MDVN dated on 2016-04-28: Why Are Medivation Shares Trading Sharply Above The \$52.50 Offer?

Financial news for MDVN dated on 2016-04-28: Goldman Sees Potential Medivation Buyout Value Near \$70/Share

Financial news for MDVN dated on 2016-04-28: JP Morgan Terminates Overweight Rating on Medivation, Removes \$48.00 PT

Financial news for MDVN dated on 2016-04-28: Citi On Medivation-Sanofi Buyout Offer: More Bidders Likely Coming

Financial news for MDVN dated on 2016-04-28: Benzinga's Volume Movers

Financial news for MDVN dated on 2016-04-28: Sanofi Wants To Acquire Medivation For \$52.50 Per Share

Financial news for MDVN dated on 2016-04-28: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for MDVN dated on 2016-04-28: Must Watch Stocks for April 28, 2016

Financial news for MDVN dated on 2016-04-28: Sanofi Offers to Acquire Medivation for \$52.50/Share in Cash

Financial news for MDVN dated on 2016-04-25: Leerink: Medivation Buyout 'Inevitable,' AstraZeneca And AbbVie Most Likely Buyers

Financial news for MDVN dated on 2016-04-20: Medivation Reports Presentation Of Phase 2 Enzalutamide Data That Suggests Potential For Further Investigation In Combo With Immunotherapy

Financial news for MDVN dated on 2016-04-19: Medivation Sells Off to Low of \$51.04 After the Open

Financial news for MDVN dated on 2016-04-19: Benzinga's Top Upgrades

Financial news for MDVN dated on 2016-04-18: Medivation Shares Break Out Over \$52 Level, Jump ~3% Over Last Few Mins

Financial news for MDVN dated on 2016-04-18: The Market In 5 Minutes: Brazil, Doha, And Earnings Season

Financial news for MDVN dated on 2016-04-18: Medivation Ticks Up 3%, AstraZeneca Said To Be Also Interested In Acquisition

Financial news for MDVN dated on 2016-04-18: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for MDVN dated on 2016-04-17: Benzinga's Weekend M&A Chatter

Financial news for MDVN dated on 2016-04-17: Medivation Presents Phase I Talazoparib Combination Data in Several Advanced Cancers at AACR Annual Meeting

Financial news for MDVN dated on 2016-04-17: AstraZeneca has Held Internal Talks Regarding a Bid for Medivation; Allergan has Yet to Make Formal Offer -Sunday Times

Financial news for MDVN dated on 2016-04-15: Medivation Spikes to High of \$51.36 on Vol

Financial news for MDVN dated on 2016-04-13: Mid-Afternoon Market Update: Dow Rises Over 1%; Medivation Shares Gain On Reported Pushback Of Sanofi Takeover Effort

Financial news for MDVN dated on 2016-04-13: SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position

Financial news for MDVN dated on 2016-04-13: Mid-Day Market Update: Repros Therapeutics Jumps Following Encouraging Study Results; Clovis Oncology Shares Drop

Financial news for MDVN dated on 2016-04-13: The Market In 5 Minutes: JPMorgan, Too Big To Fail, And Paul Carey

Financial news for MDVN dated on 2016-04-13: Mid-Morning Market Update: Markets Open Higher; JPMorgan Beats Q1 Expectations

Financial news for MDVN dated on 2016-04-13: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MDVN dated on 2016-04-13: Must Watch Stocks for April 13, 2016

Financial news for MDVN dated on 2016-04-12: Benzinga's M&A Chatter for Tuesday April 12, 2016

Financial news for MDVN dated on 2016-04-12: Medivation Surges On Reported Pushback Of Sanofi Takeover Effort

Financial news for MDVN dated on 2016-04-12: After-Hours Recap: Medivation, Valeant, CSX & More

Financial news for MDVN dated on 2016-04-12: Cancer Drug Stocks Are The Picture Of Health

Financial news for MDVN dated on 2016-04-12: Medivation Shares Spike To High Of \$50.01, Up 7.17% On Reported Pushback On Sanofi Takeover Effort; At \$49/Share

Financial news for MDVN dated on 2016-04-12: BMO Capital Initiates Coverage on Medivation at Market Perform, Announces \$47.00 PT

Financial news for MDVN dated on 2016-04-07: Medivation, Astellas Report CHMP Has Issued Positive Opinion to Include New Data in European Label for XTANDI

Financial news for MDVN dated on 2016-04-06: Why Medivation Could Be 'The Next Big Biotech'

Financial news for MDVN dated on 2016-04-05: SunTrust Robinson Humphrey Initiates Coverage on Medivation at Buy, Announces \$56.00 PT

Financial news for MDVN dated on 2016-04-04: BTIG: Medivation Acquirer Could Pay 20-30% Premium And Still Buy At Low Valuation

Financial news for MDVN dated on 2016-04-04: UPDATE: BTIG's Singh Awaiting Clarity on Medivation Amid M&A Speculation, Says 'suitor can pay 20-30% premium to current price, still be at bottom-end of 3x-5x future peak sales multiple of previous biotech M&A'

Financial news for MDVN dated on 2016-04-04: BTIG's Singh on Medivation M&A Speculation: 'Co. is at appropriate stage in Xtandi, R&D product cycle where global biopharma co. could accelerate sales, accrue operating leverage through cost synergies'

Financial news for MDVN dated on 2016-03-31: Most People Think Medivation Is A Good Takeout Target

Financial news for MDVN dated on 2016-03-31: Traders Passing Around Comments That A Medivation Sale May Prove Difficult And Costly

Financial news for MDVN dated on 2016-03-31: Mid-Afternoon Market Update: Eagle Bulk Shipping Falls Following \$105 Million Liquidity Raise Announcement; Sky Solar Shares Jump

Financial news for MDVN dated on 2016-03-31: Mid-Day Market Update: Progress Software Drops On Weak Results; Medivation Shares Surge

Financial news for MDVN dated on 2016-03-31: The Market In 5 Minutes: Thursday, March 31, 2016

Financial news for MDVN dated on 2016-03-31: Credit Suisse: Medivation Could Be Worth \$54 To \$75 In Takeout, But Management Won't Sell

Financial news for MDVN dated on 2016-03-31: Benzinga's Volume Movers

Financial news for MDVN dated on 2016-03-31: Mid-Morning Market Update: Markets Mostly Flat; Movado Issues Weak Forecast

Financial news for MDVN dated on 2016-03-31: Option Alert: MDVN Jun16 45.0 Calls Sweep: 500 @ ASK \$5.00: 500 traded vs 134 OI: Earnings 5/5 \$42.90 Ref

Financial news for MDVN dated on 2016-03-31: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for MDVN dated on 2016-03-31: Why These 7 Stocks Were Moving In After-Hours Trading

Financial news for MDVN dated on 2016-03-31: Credit Suisse Maintains Outperform on Medivation, Raises PT to \$49.00

Financial news for MDVN dated on 2016-03-31: 5 Stocks To Watch For March 31, 2016

Financial news for MDVN dated on 2016-03-30: Benzinga's M&A Chatter for Wednesday March 30, 2016

Financial news for MDVN dated on 2016-03-30: Reports: Medivation Has No Plans To Sell Itself

Financial news for MDVN dated on 2016-03-30: BZ NOTE: Encourage Caution on Sharp After-Hours Upside in Medivation, Recent Report Suggests Preliminary Interest in Co., However Reports of Interest Have Been Around Since Mar. 7

Financial news for MDVN dated on 2016-03-30: Reuters Reporting Medivation Has No Plan to Sell Itself, Hired JP Morgan to Handle Interest from Other Cos., ; Highlights 'the Move [to Hire an Advisor] is Not Uncommon in Healthcare Industry'

Financial news for MDVN dated on 2016-03-30: CNBC's Meg Tirrell Tweets 'Can confirm \$MDVN has hired advisors, but NOT with plans to sell itself.'

Financial news for MDVN dated on 2016-03-30: FBB Capital's Mike Bailey Earlier Questioned Medivation Deal Timing, Says Deal Would Raise Questions Amid Congressional Examination

Financial news for MDVN dated on 2016-03-30: Goldman Sachs Initiates Coverage on Medivation at Neutral, Announces \$44.00 PT

Financial news for MDVN dated on 2016-03-29: More Mid-Cap Biotech M&A May Be Coming

Financial news for MDVN dated on 2016-03-29: Is Medivation's Congressional Letter Just Noise?

Financial news for MDVN dated on 2016-03-29: Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price

Financial news for MDVN dated on 2016-03-28: Medivation Names Jennifer Jarrett CFO

Financial news for MDVN dated on 2016-03-28: Barclays Maintains Overweight on Medivation, Raises PT to \$48.00

Financial news for MDVN dated on 2016-03-24: UPDATE: Phase III Trial Of Enzalutamide Will Evaluate Efficacy and Safety With Androgen Deprivation Therapy vs. Placebo

Financial news for MDVN dated on 2016-03-24: Medivation Offers Pivotal Phase III Trial of Enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

Financial news for MDVN dated on 2016-03-23: Benzinga's M&A Chatter for Wednesday March 23, 2016

Financial news for MDVN dated on 2016-03-23: Medivation Shares See Support, Consolidation Just Over \$38.50 Level, Now Bouncing Over \$39, \$39.50 Levels Following Parabolic Move Amid Another Takeover Rumor

Financial news for MDVN dated on 2016-03-23: Analysts Told Benzinga Idea of Medivation as a Takeover Target is 'Nothing New,' Implied There Have Been No Recent Fundamental Changes to Suggest Co. Would Be More Attractive as Target Now

Financial news for MDVN dated on 2016-03-23: Medivation Spikes to High of \$40.80 on Chatter Sanofi Bid

Financial news for MDVN dated on 2016-03-23: Shares of Medivation Spiking Into Positive Territory, Up ~\$1.70 Over Last Min

Financial news for MDVN dated on 2016-03-22: Medivation Up As Triple M&A Interest Rumor Circulates

Financial news for MDVN dated on 2016-03-22: The Market In 5 Minutes: Tuesday, March 22, 2016

Financial news for MDVN dated on 2016-03-18: Option Alert: MDVN Apr16 41.0 Calls: 2250 @ ASK \$1.12: 2250 traded vs 297 OI: Earnings 5/5 \$35.45 Ref

Financial news for MDVN dated on 2016-03-09: U.S. FDA Lifts Partial Clinical Hold on Medivation's Pidilizumab, Potentially Pivotal Phase II Trial in DLBCL and Other Studies May Proceed

Financial news for MDVN dated on 2016-03-08: Option Alert: MDVN Apr16 43.0 Calls: 6000 @ ASK \$2.14: 6003 traded vs 19 OI: \$39.83 Ref

Financial news for MDVN dated on 2016-03-07: The Market In 5 Minutes: Monday, March 7, 2016

Financial news for MDVN dated on 2016-03-07: Medivation Being Approached by Potential Buyers, According to Ben Harrington

Financial news for MDVN dated on 2016-02-25: Medivation Sees FY16 Adj. EPS \$1.30-\$1.40 vs \$1.35 Est., Sales \$900M-\$970M vs \$910M Est.

Financial news for MDVN dated on 2016-02-25: Medivation Reports Q4 Adj. Collaboration Sales \$202.7M, Adj. EPS \$0.29 vs \$0.24 Est.

Financial news for MDVN dated on 2016-02-22: FDA Accepts XTANDI Supplemental New Drug Application For Review With Data From Head-to-Head Studies Of Enzalutamide vs. Bicalutamide

Financial news for MDVN dated on 2016-02-19: Benzinga's Top Initiations

Financial news for MDVN dated on 2016-02-19: Bank of America Initiates Coverage on Medivation at Buy

Financial news for MDVN dated on 2016-02-06: Microsoft, GoPro And 8 More Stocks To Watch Over The Weekend

Financial news for MDVN dated on 2016-02-05: Leerink Is Back On Board The Biotech Train

Financial news for MDVN dated on 2016-02-05: Leerink Swann Initiates Coverage on Medivation at Market Perform

Financial news for MDVN dated on 2016-01-27: Benzinga's Top Downgrades

Financial news for MDVN dated on 2016-01-27: Canaccord Genuity Downgrades Medivation to Hold, Lowers PT to \$45.00

Financial news for MDVN dated on 2016-01-26: UPDATE: Astellas, Medivation Announce STRIVE Trial Met Primary Endpoint Showing Significant Increase in PFS for Enzalutamid vs Bicalutamide

Financial news for MDVN dated on 2016-01-26: Astellas, Medivation Announce Publishing of Results from STRIVE Trial of Enzalutamid vs. Bicalutamide in Journal of Clinical Oncology

Financial news for MDVN dated on 2016-01-25: Medivation Announces FDA has Place MDV9300 on Clinical Hold, Company Acknowledges Drug Was Not Effective As Hoped

Financial news for MDVN dated on 2016-01-21: Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks

Financial news for MDVN dated on 2016-01-20: Credit Suisse Initiates Coverage on Medivation at Outperform, Announces \$11.00 PT

Financial news for MDVN dated on 2016-01-07: NanoString Reports Collaboration Deal with Medivation, Astellas for Development of Novel Companion Diagnostic Test

Financial news for MDVN dated on 2015-12-28: Wedbush Offers Weekly Retail Sales Tracker for Recently-Launched Drugs: Medivation's XTANDI Total Scrips Up 2.1% WoW, New Scrips Up 2.9% WoW, Repeat Scrips Up 1.7%

Financial news for MDVN dated on 2015-12-21: Medivation Begins Clinical Trial of MDV9300 in Diffuse Large B-Cell Lymphoma

Financial news for MDVN dated on 2015-11-05: Medivation Reports Q3 EPS \$0.35 Vs est \$0.33, Sales \$260.7M Vs Est \$235.75M

Financial news for MDVN dated on 2015-11-05: Medivation Reports Q3 EPS \$0.35 vs. Est. \$0.33, Rev. \$260.665M vs. Est. \$235.75M

Financial news for MDVN dated on 2015-10-28: Wild Short Interest Swings For Three Top Biotech Stocks

Financial news for MDVN dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for MDVN dated on 2015-10-12: Wild Short Interest Swings For These Three Biotech Stocks

Financial news for MDVN dated on 2015-09-29: Medivation Names Dr. Mohammad Hirmand Interim Chief Medical Officer; Dr. Lynn Seely To Retire As Chief Medical Officer

Financial news for MDVN dated on 2015-09-15: Nomura Initiates Coverage on Medivation at Buy, Announces \$140.00 PT

Financial news for MDVN dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for MDVN dated on 2015-09-14: Barclays Favorite Biotech Names For Year End Balance Are Gilead, Vertex, Medivation

Financial news for MDVN dated on 2015-09-08: A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month

Financial news for MDVN dated on 2015-09-08: UBS: Biotech Will Continue To Outperform In 2015

Financial news for MDVN dated on 2015-09-03: Benzinga's Top Initiations

Financial news for MDVN dated on 2015-08-27: Medivation Shares Spike Higher on Volume

Financial news for MDVN dated on 2015-08-24: Benzinga's M&A Chatter for Monday August 24, 2015

Financial news for MDVN dated on 2015-08-24: Medivation Announces Acquisition of Worldwide Rights to Talazoparib from BioMarin, Will Pay \$410M Upfront

Financial news for MDVN dated on 2015-08-24: Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin

Financial news for MDVN dated on 2015-08-06: Medivation Reports Q2 EPS \$0.58 vs. Est. \$0.45, Rev. \$174.8M vs. Est. \$159.42M

Financial news for MDVN dated on 2015-07-31: Morning Market Gainers

Financial news for MDVN dated on 2015-07-31: Benzinga's Top #PreMarket Gainers

Financial news for MDVN dated on 2015-07-31: Medivation Announces 2 for 1 Split

Financial news for MDVN dated on 2015-06-17: US Stock Futures Up; All Eyes On Fed Decision

Financial news for MDVN dated on 2015-06-17: UPDATE: Medivation, Astellas Report Enrollment of First Patients in Advanced Prostate Cancer

Financial news for MDVN dated on 2015-06-17: Medivation, Astellas Report Enrollment of First Patients in Advanced Prostate Cancer

Financial news for MDVN dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for MDVN dated on 2015-06-01: New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 American Society of Clinical Oncology Annual Meeting

Financial news for MDVN dated on 2015-05-17: Astellas, Medivation Announce New Enzalutamide Data Presented At The 2015 AUA Annual Meeting

Financial news for MDVN dated on 2015-05-07: Medivation Reports Q1 EPS \$0.17 Vs Est \$0.27

Financial news for MDVN dated on 2015-04-28: 3 Biotech Stocks With Rising Short Interest

Financial news for MDVN dated on 2015-04-20: Credit Suisse: Medivation 'Headwinds Loom'

Financial news for MDVN dated on 2015-04-20: Credit Suisse Downgrades Medivation to Neutral, Raises PT to \$115.00

Financial news for MDVN dated on 2015-04-02: Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial

Financial news for MDVN dated on 2015-03-30: Books-A-Million, HomeAway, Vaalco Energy Lead Monday's After-Hours Movers

Financial news for MDVN dated on 2015-03-26: 3 Biotech Stocks Bucking Short Interest Trends

Financial news for MDVN dated on 2015-03-26: What Brean Capital Thinks Of Medivation Post-TERRAIN Update

Financial news for MDVN dated on 2015-03-25: Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream

Financial news for MDVN dated on 2015-03-24: Medivation Announces Phase 2 Study Achieved Primary Objective of Statistically Significant Increase in PFS for Enzalutamide vs Bicalutamide

Financial news for MDVN dated on 2015-03-11: Wedbush Securities Reiterates Outperform, Raises PT On Medivation On Increased International Estimates

Financial news for MDVN dated on 2015-03-05: Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst

Financial news for MDVN dated on 2015-03-05: Puma Biotech Shares Up ~14%, Medivation Shares Up ~4% as RBC Analyst Suggests Oncology, Duchenne Muscular Dystrophy Group Viewed as Area for Potential M&A

Financial news for MDVN dated on 2015-02-25: Medivation Reports Q4 \$1.96 Vs Est \$1.34, Sales \$247.7M Vs Est \$235.25M

Financial news for MDVN dated on 2015-02-25: Earnings Scheduled For February 25, 2015

Financial news for MDVN dated on 2015-02-03: Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

Financial news for MDVN dated on 2015-02-02: Medivation-Astellas Report US Net Sales Of Xtandi Capsules Were \$230.2M for Quarter Ended Dec 31, 2014 vs \$181.4M for Quarter Ended Sept 30, 2014

Financial news for MDVN dated on 2015-01-22: Medivation CEO Hung Sells 100,000 Shares @ \$108.14/Share -Form 4

Financial news for MDVN dated on 2015-01-22: UPDATE: Medivation Announces Enzalutamide Phase 2 Terrain Trial Met Primary Endpoint; Shares Fall Almost 3% Premarket

Financial news for MDVN dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for MDVN dated on 2015-01-06: Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

Financial news for MDVN dated on 2015-01-06: UPDATE: Barclays Capital Initiates Coverage On Medivation On Multiple Upside Drivers

Financial news for MDVN dated on 2015-01-06: Barclays Initiates Coverage on Medivation at Overweight, Announces \$130.00 PT

Financial news for MDVN dated on 2014-12-26: William Blair's Top BioPharma Stock Picks For Q1 2015

Financial news for MDVN dated on 2014-12-23: 16 Stocks 2 Experts Are Watching This Week

Financial news for MDVN dated on 2014-12-22: Medivation Reports Exercise of License Option for Pidilizumab, Co. Responsible for Development, Commercialization; Will Make Upfront Payment of \$5M to CureTech, May Pay Milestone Payments for Up to \$85M

Financial news for MDVN dated on 2014-11-25: Medivation Appoints Joseph Lobacki As Chief Commercial Officer

Financial news for MDVN dated on 2014-11-07: Major Upgrades And Downgrades In Friday's Market Action

Financial news for MDVN dated on 2014-11-07: Brean Capital Maintains Buy on Medivation, Inc., Raises PT to \$118.00

Financial news for MDVN dated on 2014-11-06: Medivation, Inc. Reports Q3 EPS of \$0.96 vs \$0.84 Est; Revenue of \$200.50M vs \$181.96M Est

Financial news for MDVN dated on 2014-11-06: Medivation Earnings Implied Volatility ~127%; Expecting +/- \$6.74 Move

Financial news for MDVN dated on 2014-11-06: Notable Earnings After The Close: DIS, LOCO, MDVN, FSLR

Financial news for MDVN dated on 2014-10-01: Medivation Spikes to High on Volume

Financial news for MDVN dated on 2014-09-30: XTANDI Has Received Expanded Approval for FDA for Treatment of Metastatic Castration-Resistant Prostate Cancer

Financial news for MDVN dated on 2014-09-24: Benzinga's Top Downgrades

Financial news for MDVN dated on 2014-09-24: Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

Financial news for MDVN dated on 2014-09-24: Goldman Sachs Downgrades Medivation, Inc. to Neutral, Raises PT to \$110.00

Financial news for MDVN dated on 2014-09-22: These 3 Biotech Stocks Just Hit New Highs

Financial news for MDVN dated on 2014-09-18: Canaccord Genuity Raises Medivation to Buy from Hold; PT to \$132 from \$60 -Reuters

Financial news for MDVN dated on 2014-09-12: Fast Money Halftime Report Final Trade From September 12

Financial news for MDVN dated on 2014-09-11: Stifel Raises Medivation Inc Price Target

Financial news for MDVN dated on 2014-09-10: Shares of Medivation Resume Trade, Stock Now Up 3%

Financial news for MDVN dated on 2014-09-10: Shares of Medivation to Resume Trade at 4:50 p.m. EDT

Financial news for MDVN dated on 2014-09-10: Astellas, Medivation Issue Release Confirming FDA Approval for New Indication for Use of XTANDI

Financial news for MDVN dated on 2014-09-10: FDA Approves New Indication For The Use of XTANDI(R) (Enzalutamide) Capsules

Financial news for MDVN dated on 2014-09-10: UPDATE: Labeling for Medivation's Xtandi Posted on FDA Website

Financial news for MDVN dated on 2014-09-10: Medivation Xtandi Efficacy Supplement Posted on FDA Site - Bloomberg

Financial news for MDVN dated on 2014-09-10: Adam Feuerstein Tweet: \$MDVN is probably Xtandi pre-chemo approval. My guess.

Financial news for MDVN dated on 2014-09-10: Medivation Halted News Pending

Financial news for MDVN dated on 2014-09-10: Stocks Hitting 52-Week Highs

Financial news for MDVN dated on 2014-09-03: Credit Suisse Assumes Coverage on Medivation With Outperform Rating; \$98 PT -Reuters

Financial news for MDVN dated on 2014-08-08: Benzinga's Volume Movers

Financial news for MDVN dated on 2014-08-07: Medivation Shares Resumed, Stock Now Up ~4%

Financial news for MDVN dated on 2014-08-07: Medivation, Inc. Reports Q2 EPS of \$0.60; Revenue of \$143.70M Which May Not Compare \$126.46M Est

Financial news for MDVN dated on 2014-08-07: Medivation Shares Halted Ahead of Earnings

Financial news for MDVN dated on 2014-07-10: Medivation Announces Change in Executive Management Team; Dawn Svoronos To Chief Commercial Officer

Financial news for MDVN dated on 2014-07-03: Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Financial news for MDVN dated on 2014-07-02: Aegis Capital Believes Seragon Deal Underscores Value In Medivation

Financial news for MDVN dated on 2014-06-23: UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey

Financial news for MDVN dated on 2014-06-19: CORRECTION: Medivation Shares Were Not Upgraded at Jefferies Earlier, Stock Remains at Hold

Financial news for MDVN dated on 2014-06-01: Medivation, Astellas Announce New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide

Financial news for MDVN dated on 2014-05-29: 3 More Surges In Biotech Short Interest (AMGN, MDVN, PCYC)

Financial news for MDVN dated on 2014-05-22: Benzinga's Top Initiations

Financial news for MDVN dated on 2014-05-22: Stifel Nicolaus Initiates Coverage on Medivation, Inc. at Buy, Announces \$81.00 PT

Financial news for MDVN dated on 2014-05-14: Medivation to Present Enzalutamide Data at American Society of Clinical Oncology June 1

Financial news for MDVN dated on 2014-05-08: UPDATE: Medivation Shares Rise 8% After-Hours as Company Reports 2014 US Net Sales of Xtandi Exptected \$540M-\$575M

Financial news for MDVN dated on 2014-05-06: US Stock Futures Flat Ahead Of International Trade Data

Financial news for MDVN dated on 2014-05-06: Astellas, Medivation Receive Priority Review from FDA for XTANDI Capsules In Chemotherapy-Naive Advanced Prostate Cancer

Financial news for MDVN dated on 2014-04-16: UPDATE: Canaccord Genuity Initiates Coverage on Medivation as Urologist Uptake is Unclear

Financial news for MDVN dated on 2014-04-16: Canaccord Genuity Initiates Coverage on Medivation, Inc. at Hold, Announces \$60.00 PT

Financial news for MDVN dated on 2014-04-01: Morning Market Movers

Financial news for MDVN dated on 2014-04-01: Stocks To Watch For April 1, 2014

Financial news for MDVN dated on 2014-03-31: Medivation Names Bierly CFO

Financial news for MDVN dated on 2014-03-26: Celgene, Pharmacoclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

Financial news for MDVN dated on 2014-03-24: UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI(r) (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment

Financial news for MDVN dated on 2014-03-24: Astellas Announces Marketing Approval for XTANDI in Japan, Will Pay Medivation \$15M Milestone Payment

Financial news for MDVN dated on 2014-03-12: BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

Financial news for MDVN dated on 2014-02-28: Market Wrap For February 28: Markets Unable To Hold On To Gains

Financial news for MDVN dated on 2014-02-28: Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

Financial news for MDVN dated on 2014-02-28: Cowen & Company Downgrades Medivation, Inc. to Underperform

Financial news for MDVN dated on 2014-02-28: Benzinga's Top #PreMarket Losers

Financial news for MDVN dated on 2014-02-28: Jefferies Downgrades Medivation, Inc. to Hold, Lowers PT to \$90.00

Financial news for MDVN dated on 2014-02-27: Medivation Sees FY US Net Sales of XTANDI \$500-535M

Financial news for MDVN dated on 2014-02-27: Medivation, Inc. Reports Q4 EPS of \$0.03 vs \$(0.08) Est; Revenue of \$96.60M vs \$72.68M Est

Financial news for MDVN dated on 2014-02-12: Bloomberg Highlighting Comments from Medivation CEO at Leerink Swann Conference: Calls Urologists 'Very Slow' on New Therapy Uptake, Believes Change in Practice is 'Cumbersome'

Financial news for MDVN dated on 2014-02-03: Bernstein Downgrades Medivation, Inc. to Market Perform, Raises PT to \$92.00

Financial news for MDVN dated on 2014-02-03: Needham Downgrades Medivation, Inc. to Hold, Removes \$65.00 PT

Financial news for MDVN dated on 2014-01-29: Mid-Afternoon Market Update: Fed Will Continue the Taper in February

Financial news for MDVN dated on 2014-01-29: Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro Shares Rise

Financial news for MDVN dated on 2014-01-29: New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

Financial news for MDVN dated on 2014-01-29: Aegis Capital Maintains Buy on Medivation, Inc., Raises PT to \$125.00

Financial news for MDVN dated on 2014-01-29: Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts Upbeat Profit

Financial news for MDVN dated on 2014-01-29: Stocks Hitting 52-Week Highs

Financial news for MDVN dated on 2014-01-29: Benzinga's Top #PreMarket Gainers

Financial news for MDVN dated on 2014-01-29: Credit Suisse Maintains Outperform on Medivation, Inc., Raises PT to \$95.00

Financial news for MDVN dated on 2014-01-28: Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide

Financial news for MDVN dated on 2013-12-27: Medivation Spikes to High

Financial news for MDVN dated on 2013-12-20: Option Alert Medivation December \$65 Call; 2,500 Contract Trade Between Bid and Ask @\$0.20; Currently \$65.10

Financial news for MDVN dated on 2013-11-13: UPDATE: Aegis Capital Reiterates on

Medivation Following In-Line 3Q 2013 Financial Results

Financial news for MDVN dated on 2013-11-12: Medivation, Inc. Reports Q3 EPS of \$(0.18) vs \$(0.26) Est

Financial news for MDVN dated on 2013-11-04: Option Alert: Medivation November 65/February 70 Call Spread; 4,500 Spread Contract Trade; Currently \$65.69

Financial news for MDVN dated on 2013-10-22: Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide Met Co-Primary Endpoints

Financial news for MDVN dated on 2013-10-16: Option Alert: Medivation December 55/65 Call; 3,750 Spread Contracts Traded; Currently \$52.34

Financial news for MDVN dated on 2013-10-09: Option Alert: Medivation December 55 Call; 2,000 Contracts Traded @ \$5.05; Currently \$50.41

Financial news for MDVN dated on 2013-09-20: Stocks to Watch for September 20, 2013

Financial news for MDVN dated on 2013-09-18: Chardan Capital Initiates Coverage on Medivation, Inc. at Buy, Announces \$72.00 PT

Financial news for MDVN dated on 2013-08-12: Option Alert: Medivation September 65 Call; Block Trade: 2,300 Contracts @\$2.10; Currently \$56.31

Financial news for MDVN dated on 2013-08-08: Medivation, Inc. Reports Q2 EPS of \$(0.07) vs \$(0.21) Est; Revenue of \$82.40M vs \$59.93M Est

Financial news for MDVN dated on 2013-08-01: Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; William Blair Comments on Miss

Financial news for MDVN dated on 2013-07-17: UBS Upgrades Medivation, Inc. to Buy

Financial news for MDVN dated on 2013-06-24: Atellas, Medivation Announce XTANDI Authorized by EMA for Advanced Prostate Cancer

Financial news for MDVN dated on 2013-06-17: Afternoon Market Losers

Financial news for MDVN dated on 2013-06-17: J.P. Morgan Reiterates Overweight Rating on Medivation Following Aragon Pharmaceuticals Acquisition Announcement

Financial news for MDVN dated on 2013-06-17: Hearing Citigroup Defends Medivation

Financial news for MDVN dated on 2013-06-03: Astellas, Medivation Announce Health Canada Approval for XTANDI Capsules for Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Previously Treated With Docetaxel

Financial news for MDVN dated on 2013-05-24: Astellas, Medivation Announce Submission of Application for Marketing Approval of Enzalutamide in Japan

Financial news for MDVN dated on 2013-05-13: Medivation Names Stephen Kelsey SVP of New Projects

Financial news for MDVN dated on 2013-05-09: Medivation, Inc. Reports Q1 EPS of \$(0.36) vs \$(0.41) Est; Revenue of \$46.20M vs \$38.54M Est

Financial news for MDVN dated on 2013-05-09: Goldman Sachs Reiterates Buy Medivation Ahead of Q1:13 Earnings Report

Financial news for MDVN dated on 2013-05-09: Benzinga's Top Initiations

Financial news for MDVN dated on 2013-05-09: Goldman Sachs Initiates Coverage on Medivation, Inc. at Buy, Announces \$68.00 PT

Financial news for MDVN dated on 2013-05-07: Benzinga's Top Initiations

Financial news for MDVN dated on 2013-05-07: Goldman Sachs Initiates Coverage on Medivation, Inc. at Buy, Announces \$68.00 PT

Financial news for MDVN dated on 2013-04-29: Medivation Elects Wendy L. Yarno to Board of Directors

Financial news for MDVN dated on 2013-04-23: Medivation Elects Dawn Graham to Board of Directors

Financial news for MDVN dated on 2013-04-04: Medivation Shares Higher as Jefferies Gets More Aggressive on Q4 Timeline for PREVAIL, Reiterates Buy

Financial news for MDVN dated on 2013-03-28: JMP Securities Initiates Coverage on

Medivation, Inc. at Market Outperform, Announces \$55.00 PT

Financial news for MDVN dated on 2013-03-04: Needham Initiates Coverage on Medivation, Inc. at Buy, Announces \$65.00 PT

Financial news for MDVN dated on 2013-03-04: Benzinga's Top Initiations

Financial news for MDVN dated on 2013-03-01: Aegis Capital Reiterates Buy Rating, \$100 PT on Medivation on FY2012 Financial Results

Financial news for MDVN dated on 2013-02-28: Medivation, Inc. Reports Q4 EPS of \$(0.43) vs \$(0.47) Est

Financial news for MDVN dated on 2013-02-13: Medivation, Astellas to Present Enzalutamid Data at ASCO GU Symposium

Financial news for MDVN dated on 2013-02-04: Medivation Elects Kathryn Falberg to Board of Directors

Financial news for MDVN dated on 2013-02-01: Option Alert: Medivation June 70 Call; Block Trade: 1,898 Contracts @\$3.00, Currently \$56.40

Financial news for MDVN dated on 2013-02-01: Jefferies Maintains Buy on Medivation, Inc., Raises PT to \$64.00

Financial news for MDVN dated on 2013-01-02: Janney Capital Initiates Coverage on Medivation, Inc. at Buy, Announces \$69.00 PT

Financial news for MDVN dated on 2012-12-26: Aegis Capital Corp. Reiterates Buy Rating, \$100 PT on Medivation

Financial news for MDVN dated on 2012-12-19: UBS Initiates Coverage on Medivation, Inc. at Neutral, Announces \$59.00 PT

Financial news for MDVN dated on 2012-12-04: Barclays Initiates Coverage on Medivation, Inc. at Equal-weight, Announces \$56.00 PT

Financial news for MDVN dated on 2012-12-04: Benzinga's Top Initiations

Financial news for MDVN dated on 2012-11-12: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Medivation

Financial news for MDVN dated on 2012-11-12: Jefferies & Company Maintains Medivation at Buy, Raises PT from \$61 to \$62

Financial news for MDVN dated on 2012-11-09: Medivation Reports Q3 EPS \$-0.06 vs \$-0.04 Est

Financial news for MDVN dated on 2012-10-15: Jefferies & Company Maintains Medivation at Buy, Lowers PT from \$122 to \$61

Financial news for MDVN dated on 2012-10-15: Jefferies & Company Maintains Medivation at Buy, Lowers PT from \$122 to \$61

Financial news for MDVN dated on 2012-10-03: UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

Financial news for MDVN dated on 2012-10-03: Citigroup Maintains Medivation at Buy, Raises PT from \$64.50 to \$70

Financial news for MDVN dated on 2012-09-25: Aegis Capital Maintains Medivation at Buy, Lowers PT from \$175 to \$90

Financial news for MDVN dated on 2012-09-24: Medivation Effects 2-for-1 Stock Split

Financial news for MDVN dated on 2012-09-06: Brean Murray Carret Maintains Medivation at Buy, Raises PT from \$105 to \$125

Financial news for MDVN dated on 2012-09-05: Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

Financial news for MDVN dated on 2012-09-04: Wedbush Securities Maintains Medivation at Outperform, Raises PT from \$100 to \$118

Financial news for MDVN dated on 2012-09-04: Jefferies & Company Maintains Medivation at Buy, Raises PT from \$113 to \$122

Financial news for MDVN dated on 2012-09-04: Brean Murray Carret Maintains Medivation at Buy, Raises PT from \$105 to \$125

Financial news for MDVN dated on 2012-08-31: Medivation Hits 52-Week High Following FDA Approval of Prostate Cancer Drug, \$104.50

Financial news for MDVN dated on 2012-08-31: Medivation Rises 5% on Prostate Cancer Drug Approval

Financial news for MDVN dated on 2012-08-31: Medivation Resumes Trading

Financial news for MDVN dated on 2012-08-31: PREVIEW: Medivation to Resume Trading at 3:35pm

Financial news for MDVN dated on 2012-08-31: US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Financial news for MDVN dated on 2012-08-31: FDA Approves New Medivation Treatment for Prostate Cancer

Financial news for MDVN dated on 2012-08-31: Medivation Halted, Pending News

Financial news for MDVN dated on 2012-08-28: Medivation Reports 2-for-1 Forward Split of Common Stock

Financial news for MDVN dated on 2012-08-10: Aegis Capital Maintains Medivation at Buy, Raises PT from \$120 to \$175

Financial news for MDVN dated on 2012-08-10: Jefferies & Company Maintains Medivation at Buy, Raises PT from \$105 to \$113

Financial news for MDVN dated on 2012-08-09: Medivation Spiking Lower

Financial news for MDVN dated on 2012-07-26: Medivation Hits \$100

Financial news for MDVN dated on 2012-07-16: Aegis Capital Reiterates Buy Rating, \$120 PT on Medivation

Financial news for MDVN dated on 2012-07-09: UPDATE: Aegis Capital Initiates Medivation with Buy, \$120 PT on Prostate Cancer Catalysts

Financial news for MDVN dated on 2012-07-09: Aegis Captital Initiates Coverage on Medivation at Buy, Announces PT of \$120

Financial news for MDVN dated on 2012-07-03: Stocks Hitting 52-Week Highs

Financial news for MDVN dated on 2012-06-29: Four Winning Trades Based on Analyst Calls

Financial news for MDVN dated on 2012-06-29: ThinkEquity Initiates Coverage On Medivation at Buy

Financial news for MDVN dated on 2012-06-26: William Blair Maintains Medivation at Outperform, Raises PT from \$96 to \$119

Financial news for MDVN dated on 2012-06-15: Option Alert: Medivation July 85/95 Call Spread; Block Trade: 2,000 Contracts; Currently \$82.00

Financial news for MDVN dated on 2012-06-06: Medivation and Astellas Provide Update on PREVAIL Enrollment

Financial news for MDVN dated on 2012-06-04: UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

Financial news for MDVN dated on 2012-06-04: Citigroup Reiterates Buy Rating, \$129 PT for Medivation

Financial news for MDVN dated on 2012-06-04: UPDATE: J&J's Zytiga Slows Cancer Growth In Men With Prostate Cancer; Negative for Dendreon, Positive for Medivation

Financial news for MDVN dated on 2012-06-04: Benzinga's Top Pre-Market Gainers

Financial news for MDVN dated on 2012-06-04: UPDATE: Jefferies Raises PT to \$105 on Medivation on Zytiga Data

Financial news for MDVN dated on 2012-06-02: Medivation and Astellas Announce Enzalutamide Data

Financial news for MDVN dated on 2012-06-01: JP Morgan Maintains Medivation at Overweight, Raises PT from \$75 to \$135

Financial news for MDVN dated on 2012-05-31: Crazy Action in Medivation After Negative StreetSweeper Post

Financial news for MDVN dated on 2012-05-31: Medivation Spokesperson Has No Official Comment on Streetsweeper Report

Financial news for MDVN dated on 2012-05-31: UPDATE: Streetsweeper Posts Negative Article on Medivation

Financial news for MDVN dated on 2012-05-31: TheStreetSweeper Posts Negative Report on Medivation

Financial news for MDVN dated on 2012-05-31: Medivation Spikes Lower

Financial news for MDVN dated on 2012-05-30: Global Fears and Small Caps: How Much of an Impact?

Financial news for MDVN dated on 2012-05-22: Prostate Cancer Companies Suffer When They Ignore Urologists

Financial news for MDVN dated on 2012-05-16: Stocks to Watch for Thursday, May 17

Financial news for MDVN dated on 2012-05-15: Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

Financial news for MDVN dated on 2012-05-14: Watchlist for Tuesday, May 15

Financial news for MDVN dated on 2012-05-14: Medivation Trading 2.6% Higher on Heavy Volume; Currently at \$85.12

Financial news for MDVN dated on 2012-05-14: UPDATE: Citi Raises Medivation's PT

Financial news for MDVN dated on 2012-05-14: Citigroup Maintains Medivation at Buy, Raises PT from \$90 to \$129

Financial news for MDVN dated on 2012-05-09: UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

Financial news for MDVN dated on 2012-05-09: Wedbush Securities Maintains Medivation at Outperform, Raises PT from \$81 to \$86

Financial news for MDVN dated on 2012-05-08: Medivation Reports Q1 EPS \$0.01, May Not Be Comparable to \$1.16 Est; Revenues \$36.8M, May Not Be Comparable to \$73.80M Est

Financial news for MDVN dated on 2012-04-25: UPDATE: Jefferies Increases PT to \$97 on Medivation; Stellar MDV3100 Outlook

Financial news for MDVN dated on 2012-04-25: Jefferies & Company Maintains Medivation at Buy, Raises PT from \$95 to \$97

Financial news for MDVN dated on 2012-03-30: Stocks Close Out Stellar Quarter on High Note; A Look at Top Performers

Financial news for MDVN dated on 2012-03-30: Citigroup Maintains Medivation at Buy, Raises PT from \$87 to \$90

Financial news for MDVN dated on 2012-03-19: Medivation Closes 2.625% Convertible Senior Notes; Raises \$250.3M Net Proceeds

Financial news for MDVN dated on 2012-03-14: From Earlier: Medivation Prices \$225M 2.625% Convertible Senior Notes Due 2017

Financial news for MDVN dated on 2012-03-12: Medivation to Offer \$175 Million Convertible Senior Notes Due 2017

Financial news for MDVN dated on 2012-03-12: Medivation Files Mixed Security Shelf

Financial news for MDVN dated on 2012-03-08: Will Johnson & Johnson Cure Cancer?

Financial news for MDVN dated on 2012-03-08: Medivation Rises 17% on Positive J&J Zytiga

Financial news for MDVN dated on 2012-03-08: Medivation Trading 13.3% Higher on Heavy Volume; Currently at \$72.75

Financial news for MDVN dated on 2012-03-08: Medivation Shares Rise 10% on J&J's Zytiga Data, Dendreon Falls 12%

Financial news for MDVN dated on 2012-03-08: J&J's Zytiga Study to be Unblinded on

Committee Recommendation; Interim Data Could Show Clinical Benefit; Could be Positive for Medivation, Negative for Dendreon

Financial news for MDVN dated on 2012-03-02: Medivation Spiking Higher on Heavy Volume; Currently at \$66.84

Financial news for MDVN dated on 2012-03-01: Medivation Trading 4.2% Higher on Heavy Volume; Currently at \$68.26

Financial news for MDVN dated on 2012-02-29: Medivation Reports Q4 EPS \$-0.31 vs \$-0.27 Est

Financial news for MDVN dated on 2012-02-21: Notable Put Options Activity in Medivation

Financial news for MDVN dated on 2012-02-01: Benzinga's M&A Chatter for Wednesday February 1, 2012

Financial news for MDVN dated on 2012-02-01: Medivation Soars on Phase III Trial Data; Stock Up 21%

Financial news for MDVN dated on 2012-02-01: Medivation Trading 20.2% Higher on Heavy Volume; Currently at \$66.61

Financial news for MDVN dated on 2012-02-01: Jefferies Raises PT on Medivation to \$95

Financial news for MDVN dated on 2012-02-01: Wedbush Raises PT on Medivation to \$81

Financial news for MDVN dated on 2012-01-31: Medivation Rises 10% on Positive Phase 3 Results

Financial news for MDVN dated on 2012-01-31: Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy

Financial news for MDVN dated on 2012-01-31: Medivation MDV3100 Data to be Released at 6pm EST Today

Financial news for MDVN dated on 2012-01-30: JP Morgan Reiterates Overweight, \$65 PT on Medivation

Financial news for MDVN dated on 2012-01-20: Medivation Trading 3.2% Lower on Heavy Volume; Currently at \$50.56

Financial news for MDVN dated on 2012-01-20: Medivation Spiking Lower on Heavy Volume

Financial news for MDVN dated on 2012-01-17: Benzinga's Top Pre-Market Losers

Financial news for MDVN dated on 2012-01-17: A Peek Into The Market Before The Trading Starts

Financial news for MDVN dated on 2012-01-17: Financial Breakfast: Morning News Summary for January 17, 2012

Financial news for MDVN dated on 2012-01-17: Medivation Shares Fall as Much as 28% Pre-Market on Disappointing Phase 3 Results

Financial news for MDVN dated on 2012-01-17: Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer's Disease; Did Not Meet Primary Efficacy Endpoints

Financial news for MDVN dated on 2012-01-09: Medivation Announces Data From Phase 3 AFFIRM Trial of MDV3100 in Advanced Prostate Cancer to Be Highlighted in Late-Breaking Presentation at ASCO GU

Financial news for MDVN dated on 2012-01-05: JPMorgan Confab Kicks Off Biotech 2012

Financial news for MDVN dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for MDVN dated on 2011-12-21: Notable Put Options Activity in Medivation

Financial news for MDVN dated on 2011-12-05: Medivation Spiking Higher on Heavy Volume

Financial news for MDVN dated on 2011-12-05: Medivation Hits 52-Week High of \$48.00

Financial news for MDVN dated on 2011-12-02: Medivation Hits 52-Week High of \$47.39

Financial news for MDVN dated on 2011-12-01: Medivation Hits 52-Week High of \$46.17

Financial news for MDVN dated on 2011-11-30: Medivation Hits 52-Week High of \$44.94

Financial news for MDVN dated on 2011-11-10: UPDATE: JP Morgan Raises PT to \$65 on Medivation

Financial news for MDVN dated on 2011-11-10: JP Morgan Raises PT on Medivation to \$65

Financial news for MDVN dated on 2011-11-04: Medivation Hits New 52-Week High, \$40.74

Financial news for MDVN dated on 2011-11-03: End-of-Day Market Summary for November 3, 2011

Financial news for MDVN dated on 2011-11-03: This is your Benzinga news summary and traders' summary for Thursday, November 3, 2011, covering headlines from Thursday's trading session.

Financial news for MDVN dated on 2011-11-03: Top Movers; Medivation up 140%

Financial news for MDVN dated on 2011-11-03: Investor Ideas: Biopharmaceutical and Biotech Stock Alert: Medivation, Inc. Trades up over 100% on News of Positive Results of Phase 3 AFFIRM Trial

Financial news for MDVN dated on 2011-11-03: Medivation Hits New 52-Week High, \$38.84

Financial news for MDVN dated on 2011-11-03: Brean Murray Upgrades Medivation to Buy, PT raised to \$77

Financial news for MDVN dated on 2011-11-03: Rodman & Renshaw Raises PT on Medivation to \$19

Financial news for MDVN dated on 2011-11-03: Jefferies Raises PT on Medivation to \$62

Financial news for MDVN dated on 2011-11-03: Hearing Jefferies Reiterates Buy on Medivation with \$60 PT

Financial news for MDVN dated on 2011-11-03: Option Alert: Medivation November 31 Call Rises 3200% on Positive Phase 3 Results

Financial news for MDVN dated on 2011-11-03: UPDATE: Medivation Rises 140% Pre-Market on Positive Phase 3 Prostate Cancer Results

Financial news for MDVN dated on 2011-11-03: JP Morgan Upgrades Medivation to Overweight, PT Raised to \$40

Financial news for MDVN dated on 2011-11-03: Benzinga's Top Pre-Market Gainers

Financial news for MDVN dated on 2011-11-03: Financial Breakfast: Morning News Summary for November 3, 2011

Financial news for MDVN dated on 2011-11-03: Medivation Rises 90% on Phase 3 Prostate Cancer Results

Financial news for MDVN dated on 2011-11-03: Medivation and Astellas Announce Positive Survival Data From Interim Analysis of Phase 3 AFFIRM Trial of MDV3100 in Men With Advanced Prostate Cancer

Financial news for MDVN dated on 2011-11-02: Disclosure Insight Maintains High Risk Rating on Medivation

Financial news for MDVN dated on 2011-10-18: Hearing Medivation Initiated with Buy at Summer Street

Financial news for MDVN dated on 2011-10-13: Citi Maintains Buy Rating on Medivation

Financial news for MDVN dated on 2011-09-20: Jefferies Initiates Medivation at Buy, \$24 PT

Financial news for MDVN dated on 2011-09-08: Medivation Names Cheryl Cohen Chief Commercial Officer

Financial news for MDVN dated on 2011-09-07: Notable Put Options Activity in Medivation

Financial news for MDVN dated on 2011-08-09: Medivation Reports Q2 EPS \$(0.27) vs \$(0.26) Est; Revenues \$15.8M vs \$16.16M Est

Financial news for MDVN dated on 2011-08-09: Medivation Makes Breast Cancer

Breakthrough

Financial news for MDVN dated on 2011-08-04: Medivation and Astellas Announce New Preclinical Study Results Showing MDV3100 Blocks Breast Cancer Cell Growth

Financial news for MDVN dated on 2011-07-15: Buon Weekend! 07-15-2011

Financial news for MDVN dated on 2011-07-15: TGIF 07-15-2011

Financial news for MDVN dated on 2011-06-17: Bears Stop for a Pic-a-Nic 06-17-2011

Financial news for MDVN dated on 2011-06-16: Fear on the Rise 06-16-2011

Financial news for MDVN dated on 2011-06-16: Bottom-Picking - Leave It to the Proctologists 06-16-2011

Financial news for MDVN dated on 2011-06-15: Medivation Spiking Lower on Heavy Volume

Financial news for MDVN dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for MDVN dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for MDVN dated on 2011-05-10: Market Analysts coverage on 5/10/11- NRG, OLP, RIO, TAL, TRGP, VIVO, VRX, VVC, AAUKY, BHP, BOBE, CEPH, CSCO, CZZ, GPK, MDVN, NGLS, NNA

Financial news for MDVN dated on 2011-05-09: Astellas and Medivation Announce Initiation of Phase 2 Clinical (MDVN)

Financial news for MDVN dated on 2011-05-04: Global Hunter Securities Raises PT On MDVN To \$30

Financial news for MDVN dated on 2011-04-12: Medivation Hits 52-Week High (MDVN)

Financial news for MDVN dated on 2011-04-12: Benzinga's Top Downgrades (MDVN, WMS, AMMD, AA)

Financial news for MDVN dated on 2011-04-11: Hapoalim Reiterates Hold On Medivation (MDVN)

Financial news for MDVN dated on 2011-04-11: Global Hunter Maintains MDVN Buy Rating

Financial news for MDVN dated on 2011-04-11: Pre-Market Top Percentage Gainers and Losers (GLBC, LVLTT, AMMD, ENDP, RAME, VVUS, BIIB, QUIK, MDVN, JACK, EDMC, GS, SINA)

Financial news for MDVN dated on 2011-04-11: Benzinga's Top Pre-Market NASDAQ Losers (MDVN, SINA, MU, LOGI)

Financial news for MDVN dated on 2011-04-11: Medivation Resumes Trading (MDVN)

Financial news for MDVN dated on 2011-04-11: Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease

Financial news for MDVN dated on 2011-03-17: J.P. Morgan Maintains Neutral on Medivation (MDVN)

Financial news for MDVN dated on 2011-03-17: Brean Murray Reiterates Sell Rating On MDVN

Financial news for MDVN dated on 2011-02-03: Calls Purchased on Medivation, Inc. (MDVN)

Financial news for MDVN dated on 2010-12-20: Medivation Up Nearly 6% (MDVN)

Financial news for MDVN dated on 2010-12-09: Worst Biotech CEO of 2010 Is...

Financial news for MDVN dated on 2010-12-06: Options Brief: Medivation (MDVN)

Financial news for MDVN dated on 2010-12-03: Enrollment for Medivation Study - Analyst Blog

Financial news for MDVN dated on 2010-12-02: Enrollment for Medivation Study - Analyst Blog

Financial news for MDVN dated on 2010-11-22: Calls Purchased on Medivation (MDVN)

Financial news for MDVN dated on 2010-11-11: Narrower Loss at Medivation - Analyst

Blog

Financial news for MDVN dated on 2010-11-08: Hapoalim Securities Adjusts Medivation Estimates

Financial news for MDVN dated on 2010-08-11: Medivation Narrows Loss - Analyst Blog

Financial news for MDVN dated on 2010-08-10: Hapoalim Securities Reiterates Hold On Medivation (MDVN)

Financial news for MDVN dated on 2010-05-03: Medivation Receives Long Vol Trade

Financial news for MDVN dated on 2010-04-26: MDVN Upgraded To Buy

Financial news for MDVN dated on 2010-04-26: MDVN Upgraded To Buy

Financial news for MDVN dated on 2010-04-26: MDVN Upgraded To Buy

Financial news for MDVN dated on 2010-04-26: MDVN Upgraded To Buy

Financial news for MDVN dated on 2010-04-08: James Altucher Says CIGX May Surge To \$20 If It Has Found Cure To Alzheimer's

Financial news for MDVN dated on 2010-03-29: Medivation Cuts Workforce 20% (MDVN, PFE)

Financial news for MDVN dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for MDVN dated on 2010-03-16: Leerink Swann Rates Medivation (MDVN) Market Perform

Financial news for MDVN dated on 2010-03-12: Jim Cramer's Lightning Round OT Comments (SNV, MDVN, RF, FHN, HBAN, BBT)

Financial news for MDVN dated on 2010-03-10: These Biotech ETFs Gain Access To A Broader Array Of Biotech Companies

Financial news for MDVN dated on 2010-03-09: Jim Rogers Says Watch It All

Financial news for MDVN dated on 2010-03-08: Benzinga's Top Pre-Market Losers (SSTI, UTSI, MDVN, CIEN, ARMH)

Financial news for MDVN dated on 2010-03-04: Company News for March 4, 2010 - Corporate Summary

Financial news for MDVN dated on 2010-03-04: Stock Market News for March 4, 2010 - Market News

Financial news for MDVN dated on 2010-03-03: Medivation Inc. (MDVN) Shows All Signs Of Moving Into Deep Correction

Financial news for MDVN dated on 2010-03-03: Benzinga's Top Downgrades (LCAV, MDVN, VISN, HELE, LCC)

Financial news for MDVN dated on 2010-03-03: MDVN's Dimebon Fails To Meet Endpoints In AD Study

Financial news for MDVN dated on 2010-03-03: Tuesday's Hot Stocks: One Fahionable Option Trade

Financial news for MDVN dated on 2010-03-03: Medivation Slumps On Failed Phase III Trial (MDVN, PFE)

Financial news for MDVN dated on 2010-03-03: Benzinga's Top Pre-Market Losers (MDVN, VISN, CMED, CPNO)

Financial news for MDVN dated on 2010-03-02: Crazy Biotech Bid Ups

Financial news for MDVN dated on 2010-02-08: Pete Najarian Is Watching Medivation (MDVN)

Financial news for MDVN dated on 2010-02-05: Benzinga's Volume Movers (SFLY, MPWR, OTEX, MDVN, ABCO)

Financial news for MDVN dated on 2010-02-02: Market Round-up (TM, HMC, PFE, MDVN, KFT, CBY)

Financial news for MDVN dated on 2010-02-02: Medicine From Pfizer To Benefit

Alzheimer's Patients (MDVN, PFE)

Financial news for MDVN dated on 2009-12-23: Pete Najarian Is Bullish On JNJ And MDVN

Financial news for MDVN dated on 2009-11-05: Medivation upgraded to Buy at Roth Capital

Financial news for MDVN dated on 2009-10-29: JP Morgan Starts Coverage on Medivation With A Buy, And A \$45 Price Target

Financial news for MDVN dated on 2009-10-27: Astellas and Medivation Enter Into Worldwide Agreement (MDVN), Medivation To Receive \$110M Up-Front